U.S. Markets close in 1 hr 28 mins

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
311.30-8.50 (-2.66%)
As of 2:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close319.80
Open322.28
Bid311.15 x 1100
Ask312.06 x 1400
Day's Range311.26 - 323.24
52 Week Range212.66 - 382.15
Volume101,415
Avg. Volume181,782
Market Cap16.115B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-14.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est339.31
  • Reuters

    Argenx's drug effective against muscle-weakening disease myasthenia gravis

    An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the Lancet Neurology medical journal on Wednesday. The late-stage study met its main goal of demonstrating that a greater percentage of patients on the treatment showed improvement in their daily activities compared to those on placebo. The study enrolled 167 participants to evaluate argenx's lead drug, efgartigimod, which seeks to reduce a type of disease-causing antibodies commonly found in patients with the chronic, rare autoimmune disorder called generalized myasthenia gravis.

  • argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
    GlobeNewswire

    argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

    Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG) Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date Breda, the Netherlands —Jun. 16, 2021— argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAP

  • This Biotech Stock Has Big Potential
    Barrons.com

    This Biotech Stock Has Big Potential

    The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.